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dialysis patients, especially when the evi-
dence supporting daily dietary sodium 
intake of 2  g is not strong. 
 In conclusion, the cardiovascular mor-
tality in the dialysis population is multifac-
torial, and high sodium intake is just one 
of the players in this context ( Figure 1 ). It 
took years to understand the role of dietary 
sodium in morbidity and mortality in 
healthy populations; in patients on chronic 
dialysis we are just at the beginning. 
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 Renal fi brosis is the underlying patho-
logical alteration and end point of most, if 
not all, progressive kidney diseases. Fibro-
sis is considered a uniform process defi ned 
as exaggerated deposition of non-
functional scar tissue comprising extracel-
lular matrix and (myo) fi broblasts. It is 
most oft en associated with injured or atro-
phied tubules and inflammatory infil-
trates. Understanding the mechanisms 
and molecules involved in renal fi brosis 
could lead to identifi cation of novel, eff ec-
tive treatments, which we are currently 
lacking. 1 Nakagawa and colleagues 2 
(this issue) present the fi rst step in the 
identifi cation of such a novel molecule: 
the prostaglandin E 2 receptor EP 4 . 2 
 Prostaglandin E 2 (PGE 2 ) is one of the 
major prostanoids and the most abundant 
one in the kidney. It is synthesized pre-
dominantly from arachidonic acid via the 
rate-limiting enzymes cyclooxygenase-1 
and -2 (COX-1 and -2) and prostaglandin 
E synthase ( Figure 1a ). All prostanoids 
bind to G protein-coupled receptors with 
seven transmembrane domains. PGE 2 has 
four receptors, termed EP 1 , EP 2 , EP 3 , and 
EP 4 . Each has a slightly diff erent down-
stream signaling ( Figure 1a ). 3 
 Nakagawa and colleagues 2 used the 
unilateral ureteral obstruction (UUO) 
model in mice, a widely used model of 
interstitial fi brosis. Th ey fi rst described 
the regulation of COX and EP receptors 
in obstructed kidneys compared with 
non-obstructed ones. COX enzymes are 
the rate-limiting step in prostanoid syn-
thesis, and their upregulation is a neces-
sary step in increased synthesis of these 
lipid mediators. In the obstructed kidneys, 
COX-2 mRNA was increased up to three-
fold already at day 1 of UUO and remained 
upregulated at this level thereaft er. Inter-
estingly, the authors also observed a slight 
but significant upregulation of COX-1 
mRNA, that is, of the isoform considered 
to be constitutively expressed. Th ese data 
further extend previous studies showing 
increased synthesis of prostanoids, includ-
ing PGE 2 , via increased COX expression 
in the UUO model. 4,5 Next the authors 
analyzed the expression of PGE 2 recep-
tors. EP 1 was not regulated whereas EP 2 
was signifi cantly increased on day 7, and 
EP 4 was even more strongly upregulated 
on both day 4 and day 7 aft er UUO. EP 3 , 
a receptor with antagonistic signaling 
compared with EP 2 and EP 4 ( Figure 1a ), 
was significantly downregulated at 
all examined time points. The authors 
also analyzed the localization of COX-2 
(by immunofl uorescence) and EP 4 (by 
 in situ hybridization). Both were nearly 
undetectable in normal kidneys, strongly 
upregulated in UUO kidneys, and mainly 
localized in tubular cells. Th e EP 4 signal 
was also observed in interstitial cells. In 
line with these  in vivo fi ndings, stimula-
tion of primary tubular cells with profi -
brotic transforming growth factor-  1 
induced EP 4 mRNA expression. Taken 
together, these results suggest that COX –
 PGE 2 – EP 4 represents an inducible system 
strongly upregulated during ureter 
obstruction. Interestingly, in another 
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widely used model of renal fi brosis follow-
ing 5 / 6 nephrectomy in rats, EP 4 was not 
regulated and EP 2 was even decreased. 6 
Production of prostanoids and expression 
of their receptors diff er not only between 
healthy and diseased kidneys but also 
between the anatomical parts within the 
kidney, that is, between the cortex and 
various portions of the medulla. 5 Albeit 
technically challenging, the anatomical 
and cellular localization and regulation of 
the COX – EP system at the protein level 
during experimental and, more impor-
tantly, during human fibrosis deserve 
further characterization. 
 Next Nakagawa and colleagues 2 set 
out to manipulate EP 4 . First they showed 
that, compared with wild-type mice, EP 4 -
defi cient female mice had signifi cantly 
increased interstitial fi brosis on day 7 (Sir-
ius red staining and hydroxyproline), an 
increased number of myofi broblasts on 
days 4 and 7 (  -smooth muscle actin 
immunohistochemistry), and an increased 
number of monocytes / macrophages /
 dendritic cells on days 4 and 7 (F4 / 80   +  
cells). Th is was accompanied by increased 
mRNA for chemokines (monocyte chemo-
attractant protein-1, RANTES) and profi -
brotic growth factors (transforming 
growth factor-  1 , connective tissue growth 
factor). Th ese data suggested that EP 4 lim-
its fi brosis and infl ammatory infi ltrates 
aft er UUO. However, wild-type and EP 4 
knockout mice were on a mixed back-
ground (129 / Ola – C57BL / 6) but were 
bred independently. If mice are bred 
separately from their parent colony, 
inevitably genetic drift  occurs, in particu-
lar in mixed-background colonies. Such 
genetic drift  is the reason why there are 
currently more than 40 substrains of 
C57BL / 6 mice that diff er substantially in 
their phenotype. As the authors mention 
themselves, it remains unknown to what 
extent the observed differences might 
have been due to the dissimilar back-
ground between WT and EP 4 knockout 
mice. To confi rm their fi nding, the authors 
treated wild-type mice with an EP 4 -
specifi c agonist. Compared with untreated 
mice, EP 4 agonist-treated mice had sig-
nificantly reduced interstitial fibrosis, 
number of myofi broblasts, infl ammatory 
infiltrates, and mRNA expression of 
chemokines and profi brotic factors. Th e 
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 Figure 1  |  Scheme of prostanoids synthesis and of the role of EP 4 in rebal fibrosis. 
( a ) Simplified scheme of the synthesis of major prostanoids and their receptors. Major prostanoids 
are thromboxane (TXA 2 ), prostacyclin (PGI 2 ), and prostaglandins E 2 , D 2 , and F 2   (PGE 2 , PGD 2 , 
PGF 2   ). The rate-limiting step of prostanoid synthesis is the conversion of arachidonic acid 
to prostaglandin H 2 (PGH 2 ) by cyclooxygenase-1 (considered a constitutive enzyme) and 
cyclooxygenase-2 (considered an inducible enzyme). PGH 2 serves as a precursor for synthesis of 
all other prostanoids via the respective synthases, that is, TX, PGI, PGE, PGD, and PGF synthases. 
Prostanoids exert their pleiotropic functions via rhodopsin-type membrane-bound receptors 
coupled to G proteins, termed TP, IP, FP, DP, and EP. PGE 2 , the most abundant prostanoid, has four 
receptors, EP 1 – EP 4 . EP 2 and EP 4 are coupled to G s protein and, upon ligand binding, increase 
intracellular cyclic adenosine monophosphate (cAMP) levels. EP 1 is coupled to G q protein and, 
upon ligand binding, increases intracellular calcium (Ca 2  +   ). EP 3 is coupled to G i protein and, 
upon ligand binding, reduces intracellular cAMP. Other signaling pathways have been proposed 
to be activated by EP receptors; for example, EP 4 may activate the phosphatidylinositol-3-kinase 
(PI3K) pathway. The pathway analyzed by Nakagawa  et al. 2 is highlighted in blue. 
( b ) Proposed role of EP 4 in renal fibrosis induced by unilateral ureteral obstruction (UUO). 
In murine obstructed kidneys, cyclooxygenase-2 (COX-2), PGE 2 , and EP 4 are upregulated. 
COX-2 seems to be mainly localized in tubular cells. EP 4 is found in tubular cells but also to a 
certain extent in interstitial cells. The  in vitro studies suggest that these interstitial cells are possibly 
fibroblasts; perhaps some are also inflammatory cells. The precise localization and regulation 
of these proteins during fibrosis in regard to various kidney compartments, that is, vasculature, 
cortex, and outer and inner medulla, are not yet known. It is also not clear whether EP 4 knockout 
or EP 4 agonist regulates the expression of COX-2 or EP 4 . Tubular cells in UUO kidneys undergo 
phenotypic alterations, atrophy, and, among others, express chemokines, such as monocyte 
chemoattractant protein-1 (MCP-1) and RANTES, which drive the influx of leukocytes. In the 
interstitium, fibroblasts undergo a phenotypic switch to myofibroblasts, proliferate, and produce 
exaggerated amounts of extracellular matrix (fibrosis). Obstructed kidneys of EP 4 knockout mice 
have exaggerated fibrosis, myofibroblast numbers, inflammatory infiltrates, and MCP-1 and 
RANTES mRNA expression. On the other hand, UUO kidneys of mice treated with the EP 4 agonist 
have significantly reduced fibrosis, myofibroblast numbers, inflammatory infiltrates, and MCP-1 
and RANTES mRNA expression.  
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specifi city of the EP 4 agonist was elegantly 
shown as treatment of EP 4 knockout mice 
(or cells  in vitro ) had no eff ect on any of 
the analyzed parameters. 
 To further confi rm that the antifi brotic 
eff ects of EP 4 were truly renoprotective, 
the authors used a model that allowed 
assessment of renal function — folic acid-
induced nephropathy. Th ey killed mice at 
day 7, a time point that might rather rep-
resent acute injury. However, the authors 
show that already at this stage, renal 
hydroxyproline content, that is, fi brosis, 
increases twofold compared with that in 
control animals. Treatment with the EP 4 
agonist signifi cantly reduced interstitial 
fibrosis, and, even more important, it 
ameliorated the increase in serum creati-
nine and blood urea nitrogen. Th ese fi nd-
ings are well in line with a previous study 
that showed that rats with nephrotoxic 
(HgCl 2 ) acute kidney failure treated with 
EP 4 agonist had signifi cantly improved 
serum creatinine, survival, tubular injury, 
and tubular apoptosis, whereas treatment 
with EP 2 or EP 2 / EP 4 agonists had benefi -
cial but less striking eff ects. 6 In rats with 
chronic kidney injury, that is, with 5 / 6 
nephrectomy, all agonists (EP 4 , EP 2 , and 
EP 2 / EP 4 ) reduced serum creatinine, 
glomerulosclerosis, interstitial fi brosis, 
and   -smooth muscle actin expression 
and better preserved tubular epithelium 
with increased proliferation and reduced 
apoptosis. 6 
 Nakagawa and co-workers 2 also per-
formed  in vitro studies using primary 
renal tubular cells and fi broblasts. In tubu-
lar cells, the authors showed that the EP 4 
agonist reduced the expression of   -
smooth muscle actin and Twist, markers 
of epithelial-to-mesenchymal transition. 
Th e role of EMT in renal fi brosis and its 
relevance  in vivo are currently controver-
sially debated. 1 Th e discrepancy between 
 in vitro and  in vivo fi ndings was also illus-
trated in the study by Nakagawa  et al. 2 Th e 
authors show immunohistochemistry for 
  -smooth muscle actin in unobstructed 
and obstructed kidneys with no positive 
staining in tubular cells at all. It would be 
interesting to know whether incubation of 
tubular cells with the EP 4 agonist could 
reduce production of extracellular matrix 
proteins or profi brotic cytokines, such 
as platelet-derived growth factor-BB 
or transforming growth factor-  1 (see 
below). 
 In another set of experiments, the 
authors showed that treatment with the 
EP 4 agonist reduced proliferation of pri-
mary renal fibroblasts stimulated with 
platelet-derived growth factor-BB in a 
dose-dependent manner. Stimulation of 
fi broblasts with transforming growth fac-
tor-  1 induced production of profi brotic 
connective tissue growth factor mRNA, 
which was also abrogated by treatment 
with the EP 4 agonist. 
 What are the potential antifibrotic 
mechanisms of EP 4 ( Figure 1b )? One 
exciting possibility is that PGE 2 , produced 
mostly by tubular cells, where the major-
ity of COX-2 expression is localized, acts 
in a paracrine manner via EP 4 on intersti-
tial fi broblasts, reducing their prolifera-
tion. Another mechanism, not yet assessed 
in renal fi broblasts, could be increased 
apoptosis of fi broblasts. PGE 2 – EP 4 was 
shown to induce apoptosis of lung fi brob-
lasts by acting on several survival path-
ways. 7 On the other hand, for many other 
cell types, including renal tubular cells, 
the PGE 2 – EP 4 system acts in an antiapop-
totic way as a survival factor. 8 PGE 2 – EP 4 
could represent a system that reduces the 
survival of interstitial fi broblasts on the 
one hand and improves the survival and 
perhaps regeneration of tubular cells on 
the other hand. Another mechanism 
could be an autocrine eff ect of PGE 2 on 
tubular cells, reducing their production of 
chemokines, thereby reducing infl amma-
tory infi ltrates. Taken together, previous 
studies and the work of Nakagawa and 
colleagues 2 provide strong evidence that 
PGE 2 – EP 4 is a potent endogenous reno-
protective system limiting renal fi brosis by 
acting on multiple cellular targets. 
 Is this the treatment we have been 
searching for? Th e answer might not be so 
simple, at least at the moment. Clinical 
tools are already available: there are clini-
cal studies, published or ongoing, that are 
testing the effects of EP 4 agonists (for 
example, in ulcerative colitis), but also of 
EP 4 antagonists (for example, for chronic 
infl ammatory pain). However, in contrast 
to the discussed studies, 2,6 it was shown 
that podocyte-specifi c overexpression of 
desensitization-resistant EP 4 resulted 
in aggravated renal injury and reduced 
survival aft er 5 / 6 nephrectomy, whereas 
podocyte-specifi c EP 4 deletion signifi -
cantly reduced renal injury. 9 If confi rmed, 
such diff erential eff ects of EP 4 in glomer-
uli versus interstitium could limit the use 
of an agonist in progressive glomerular 
diseases with podocyte injury. Th e pleio-
tropic functions of PGE 2 – EP 4 in health 
and disease might also limit its translation 
into clinical practice. Any treatment for 
renal fi brosis will have to be a long-term 
therapy and as such should be safe with 
as few side eff ects as possible. One possi-
ble safety issue might be the fact that 
activation of PGE 2 – EP 4 was shown to 
be antiapoptotic, and to promote tumor 
metastasis or tumor invasion, for instance, 
in renal-cell carcinoma. 10 As is so oft en 
stated at the end of commentaries such as 
this, clearly we need more studies. 
Whether EP 4 agonists will make it to 
the clinic or not, the elegant study by 
Nakagawa and colleagues 2 provides new 
pieces of the complicated puzzle called 
renal fi brosis. 
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 A physician ’ s perseverance 
uncovers problems in a key 
nephrology study 
 Steven  Fishbane 1 and  Jay B.  Wish 2  
 The Normal Hematocrit Cardiac Trial, published in 1998, was a 
foundational study testing erythropoietin analog treatment to normal 
hematocrit targets. It served as a warning that erythropoietin 
replacement was not a panacea. Its large size gave it disproportionate 
weighting in evidence reviews and guideline development and thereby 
impacted treatment decisions. Coyne shows that the published results 
did not completely and clearly represent the study ’ s actual results. We 
discuss the implications and make recommendations to prevent such 
occurrences. 
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 In this issue of  Kidney International , 
 Daniel W. Coyne 1 reports on critical dis-
crepancies between the 1998 publication 
of the Amgen-sponsored Normal Hema-
tocrit Cardiac Trial (NHCT) 2 and the 
actual study data as presented to the US 
Food and Drug Administration (FDA) in 
the 1996 Clinical Trial Report. It took 
more than two years and repeated prod-
ding for the study data to become avail-
able. The implications are remarkably 
important for the nephrology commu-
nity — practice guidelines based on erro-
neous data, the real possibility that 
patients may have been harmed as a 
result, and a need to understand why one 
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of the field ’ s foundational studies was 
reported with such a fundamental lack of 
clarity and completeness. 
 Th e NHCT was well intended from its 
inception, testing an implied hypothesis 
that normalization of hematocrit (Hct) 
with epoetin treatment would improve 
outcomes. The rationale was sound; 
greater oxygen carriage to organs and tis-
sues in patients with cardiovascular dis-
ease had a plausible likelihood of being 
beneficial. In total, 1233 hemodialysis 
patients with evidence of cardiac disease 
were randomized to receive epoetin alfa 
treatment to one of two Hct targets, 
30 ± 3 % or 42 ± 3 % . Th e median follow-up 
was 14 months, and the longest duration 
of treatment was 30 months. 
 Coyne 1 exposed a number of inconsist-
encies in the 1998 NHCT publication. Th e 
primary end point reporting (death or 
nonfatal myocardial infarction) was from 
the last interim analysis, adjusted for Data 
Safety Monitoring Board repeated meas-
ures, and gave the impression of statisti-
cally insignifi cant diff erences between the 
groups. Coyne found that this was not 
clearly reported; there actually was a sta-
tistically signifi cant increase in risk in the 
high-Hct group,  P  =  0.0119. Th e 95 % con-
fi dence intervals given in the abstract and 
body of the 1998  New England Journal of 
Medicine paper 2 were actually the 99.912 % 
confi dence intervals adjusted for repeated 
measures by the Data Safety Monitoring 
Board. Th e original article failed to apply 
statistical testing to the critically impor-
tant outcome of all-cause deaths; Coyne 
found there to be a statistically signifi cant 
increase in deaths in the high-Hct group, 
relative risk 1.26, 95 % confi dence interval 
1.02 – 1.56, at the last interim analysis, con-
sistent with the final trial data of 1.27 
(1.04 – 1.54) as now reported by the FDA. 
Additionally, the NHCT article failed to 
report on an important safety risk from 
the clinical trial report, other thrombotic 
events; Coyne found these to be increased 
in the high-Hct group (22.4 vs. 17.6 % , 
 P  =  0.041). 1,2 
 Th ere is a widespread misconception 
that the study found a signifi cant improve-
ment in quality of life with the higher Hct 
target; this is not correct. Th e protocol 
specifi ed quality of life as a secondary out-
come, which would typically mean a com-
parison of quality-of-life outcomes 
between the two treatment groups. Th is 
did not occur; instead the 1998 publica-
tion reported on quality of life only in 
relation to achieved Hct level without 
respect to study group allocation ( ‘ Th e 
physical-function score on the quality-of-
life questionnaire at 12 months increased 
by 0.6 point for each percentage-point 
increase in the hematocrit ( P  =  0.03). For 
example, an increase in the hematocrit 
from 30 percent to 42 percent was associ-
ated with a clinically meaningful increase 
of 7.2 points in the score on the physical-
function scale ’ 2 ). Th is reporting was prob-
lematic for the following reasons: 
 (1)  As a specifi ed secondary end point, 
the credible outcome to report is the 
result of the outcome in each group, 
together with the diff erence bet-
ween the groups, the eff ect size. 3 
 (2)  A secondary,  post hoc analysis by 
achieved Hct level would have been 
acceptable, but only aft er reporting 
